BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hayakawa K, Kurano M, Ohya J, Oichi T, Kano K, Nishikawa M, Uranbileg B, Kuwajima K, Sumitani M, Tanaka S, Aoki J, Yatomi Y, Chikuda H. Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis. Sci Rep 2019;9:9144. [PMID: 31235770 DOI: 10.1038/s41598-019-45742-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Gong P, Wang M, Yang W, Chang X, Wang L, Chen F. Integrated metabolomics coupled with pattern recognition and pathway analysis to reveal molecular mechanism of cadmium-induced diabetic nephropathy. Toxicol Res (Camb) 2021;10:777-91. [PMID: 34484669 DOI: 10.1093/toxres/tfab059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ueda H. Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. Prog Lipid Res 2021;81:101079. [PMID: 33259854 DOI: 10.1016/j.plipres.2020.101079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Balzani E, Fanelli A, Malafoglia V, Tenti M, Ilari S, Corraro A, Muscoli C, Raffaeli W. A Review of the Clinical and Therapeutic Implications of Neuropathic Pain. Biomedicines 2021;9:1239. [PMID: 34572423 DOI: 10.3390/biomedicines9091239] [Reference Citation Analysis]
4 Ueda H. LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia. Pain Manag 2020;10:43-53. [PMID: 31852400 DOI: 10.2217/pmt-2019-0036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
5 Uranbileg B, Ito N, Kurano M, Kano K, Uchida K, Sumitani M, Aoki J, Yatomi Y. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis. Sci Rep 2021;11:3984. [PMID: 33597645 DOI: 10.1038/s41598-021-83569-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kano K, Aoki J, Hla T. Lysophospholipid Mediators in Health and Disease. Annu Rev Pathol 2022;17:459-83. [PMID: 34813354 DOI: 10.1146/annurev-pathol-050420-025929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Sadler KE, Moehring F, Shiers SI, Laskowski LJ, Mikesell AR, Plautz ZR, Brezinski AN, Mecca CM, Dussor G, Price TJ, McCorvy JD, Stucky CL. Transient receptor potential canonical 5 mediates inflammatory mechanical and spontaneous pain in mice. Sci Transl Med 2021;13:eabd7702. [PMID: 34039739 DOI: 10.1126/scitranslmed.abd7702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ahmad S, Orellana A, Kohler I, Frölich L, de Rojas I, Gil S, Boada M, Hernández I, Hausner L, Bakker MHM, Cabrera-Socorro A, Amin N, Ramírez A, Ruiz A, Hankemeier T, Van Duijn CM. Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease. Alzheimers Res Ther 2020;12:124. [PMID: 33008436 DOI: 10.1186/s13195-020-00680-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ren J, Lin J, Yu L, Yan M. Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain. IJMS 2022;23:8274. [DOI: 10.3390/ijms23158274] [Reference Citation Analysis]
10 Li S, Xu B, Liu Y, Zhang J, Xu G, Shao P, Li X, Hu Y, Ma X. Biomechanical Evaluation of Spinal Column after Percutaneous Cement Discoplasty: A Finite Element Analysis. Orthop Surg 2022. [PMID: 35818350 DOI: 10.1111/os.13314] [Reference Citation Analysis]
11 Zhai G, Liang W, Xu Y. High Expression of Lysophosphatidic Acid Induces Nerve Injury in LSS Patients via AKT Mediated NF-κB p65 Pathway. Front Pharmacol 2021;12:641435. [PMID: 33815123 DOI: 10.3389/fphar.2021.641435] [Reference Citation Analysis]
12 Mosca MG, Mangini M, Cioffi S, Barba P, Mariggiò S. Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning. Cell Commun Signal 2021;19:48. [PMID: 33902596 DOI: 10.1186/s12964-021-00727-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Uranbileg B, Ito N, Kurano M, Saigusa D, Saito R, Uruno A, Kano K, Ikeda H, Yamada Y, Sumitani M, Sekiguchi M, Aoki J, Yatomi Y. Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model. Sci Rep 2019;9:16578. [PMID: 31719574 DOI: 10.1038/s41598-019-52999-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]